Skip to main content

Advertisement

SpringerLink
Log in

NRP-1 expression in bladder cancer and its implications for tumor progression

  • Research Article
  • Published:
Tumor Biology

Abstract

Neuropilin-1 (NRP-1) overexpression has been reported in a variety of human cancers. However, the role of NRP-1 in bladder cancer (BC) remains unclear. The aim of present study was to analyze NRP-1 protein expression in BC tissues and to assess its prognostic significance for BC. NRP-1 messenger ribonucleic acid (mRNA) and protein expression were determined by real-time quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and immunohistochemistry in specimens of primary cancer and their adjacent noncancerous tissues in BC patients. Additionally, NRP-1 protein expression in 139 archived paraffin-embedded BC samples was analyzed by immunohistochemistry and correlated with clinicopathological characteristics and survival. Student’s t test, Spearman’s rank correlation, Kaplan-Meier plots, and Cox’s proportional hazards regression model were used to analyze the data. By qRT-PCR and immunohistochemistry, the levels of NRP-1 mRNA and protein were significantly higher in BC, compared to that in adjacent noncancerous tissues (P < 0.001). High expression of NRP-1 was significantly associated with histologic grade (P = 0.016) and tumor stage (P = 0.001). Multivariate analysis showed that high expression of NRP-1 was an independent prognostic factor for overall survival. Our study suggests that overexpression of NRP-1 may play an important role in the progression of BC, and NRP-1 expression may serve as a biomarker for poor prognosis for BC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Liou LS. Urothelial cancer biomarkers for detection and surveillance. Urology. 2006;67:25–33. doi:10.1016/j.urology.2006.01.034. discussion 33–24.

    Article  PubMed  Google Scholar 

  2. Smaldone MC, Jacobs BL, Smaldone AM, Hrebinko Jr RL. Long-term results of selective partial cystectomy for invasive urothelial bladder carcinoma. Urology. 2008;72:613–6. doi:10.1016/j.urology.2008.04.052.

    Article  PubMed  Google Scholar 

  3. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. Cell. 1997;90:739–51.

    Article  CAS  PubMed  Google Scholar 

  4. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell. 1997;90:753–62. doi:10.1016/S0092-8674(00)80535-8.

    Article  CAS  PubMed  Google Scholar 

  5. Kitsukawa T, Shimono A, Kawakami A, Kondoh H, Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development. 1995;121:4309–18.

    CAS  PubMed  Google Scholar 

  6. Kawasaki T, Kitsukawa T, Bekku Y, Matsuda Y, Sanbo M, Yagi T, et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 1999;126:4895–902.

    CAS  PubMed  Google Scholar 

  7. Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB J. 2000;14:2532–9. doi:10.1096/fj.00-0250com.

    Article  CAS  PubMed  Google Scholar 

  8. Ding H, Wu X, Roncari L, Lau N, Shannon P, Nagy A, et al. Expression and regulation of neuropilin-1 in human astrocytomas. Int J Cancer. 2000;88:584–92.

    Article  CAS  PubMed  Google Scholar 

  9. Latil A, Bièche I, Pesche S, Valéri A, Fournier G, Cussenot O, et al. VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer. 2000;89:167–71.

    Article  CAS  PubMed  Google Scholar 

  10. Fakhari M, Pullirsch D, Abraham D, Paya K, Hofbauer R, Holzfeind P, et al. Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and −2 in human neuroblastoma. Cancer. 2002;94:258–63.

    Article  CAS  PubMed  Google Scholar 

  11. Kawakami T, Tokunaga T, Hatanaka H, Kijima H, Yamazaki H, Abe Y, et al. Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer. 2002;95:2196–201. doi:10.1002/cncr.10936.

    Article  CAS  PubMed  Google Scholar 

  12. Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda A, Fan F, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer. 2003;88:796–802. doi:10.1038/sj.bjc.6600811.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Parikh AA, Liu WB, Fan F, Stoeltzing O, Reinmuth N, Bruns CJ, et al. Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma. Cancer. 2003;98:720–9. doi:10.1002/cncr.11560.

    Article  CAS  PubMed  Google Scholar 

  14. Hansel DE, Wilentz RE, Yeo CJ, Schulick RD, Montgomery E, Maitra A. Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. Am J Surg Pathol. 2004;28:347–56.

    Article  PubMed  Google Scholar 

  15. Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61:5736–40.

    CAS  PubMed  Google Scholar 

  16. Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, et al. A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells. Br J Cancer. 2005;92:328–33. doi:10.1038/sj.bjc.6602308.

    PubMed Central  CAS  PubMed  Google Scholar 

  17. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203–6.

    CAS  PubMed  Google Scholar 

  18. Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ, et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res. 2003;63:5230–3.

    CAS  PubMed  Google Scholar 

  19. Parikh AA, Fan F, Liu WB, Ahmad SA, Stoeltzing O, Reinmuth N, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol. 2004;164:2139–51.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, et al. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 Candidate tumor suppressor gene SEMA3B. Proc Natl Acad Sci U S A. 2001;98:13954–9. doi:10.1073/pnas.231490898.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Tse C, Xiang RH, Bracht T, Naylor SL. Human semaphorin 3B (SEMA3B) located at chromosome 3p21.3 suppresses tumor formation in an adenocarcinoma cell line. Cancer Res. 2002;62:542–6.

    CAS  PubMed  Google Scholar 

  22. Castro-Rivera E, Ran S, Thorpe P, Minna JD. Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci U S A. 2004;101:11432–7. doi:10.1073/pnas.0403969101.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Gospodarowicz MK. Staging of bladder cancer. Semin Surg Oncol. 1994;10:51–9.

    Article  CAS  PubMed  Google Scholar 

  24. Hussain SA, James ND. Molecular markers in bladder cancer. Semin Radiat Oncol. 2005;15:3–9. doi:10.1016/j.semradonc.2004.07.007.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was also supported by the National Natural Science Foundation of China (No. 30772278 and No. 30973443).

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, Nanjing Jinling Hospital, Nanjing University School of Medicine, No. 305, Zhongshandong Road, Nanjing, 210002, China

    Wen Cheng, Dian Fu, Zhi-Feng Wei, Feng Xu, Xiao-Feng Xu, You-Huang Liu, Jing-Ping Ge, Feng Tian, Zheng-Yu Zhang & Li-Ming Zhou

  2. Department of Urology, The Affiliated School of Clinical Medicine of Xuzhou Medical College, Xuzhou Central Hospital, No. 199 Jiefangnan Road, Xuzhou, 221009, China

    Cong-Hui Han

Authors
  1. Wen Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dian Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhi-Feng Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-Feng Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. You-Huang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jing-Ping Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Feng Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cong-Hui Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zheng-Yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Li-Ming Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Wen Cheng, Zheng-Yu Zhang or Li-Ming Zhou.

Additional information

Wen Cheng, Dian Fu and Zhi-Feng Wei contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, W., Fu, D., Wei, ZF. et al. NRP-1 expression in bladder cancer and its implications for tumor progression. Tumor Biol. 35, 6089–6094 (2014). https://doi.org/10.1007/s13277-014-1806-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1806-3

Keywords

Search

Navigation